As a confirmation of the potential efficacy of CSC-targeted treatment, clinical studies have demonstrated significant benefits in colorectal and pancreatic cancer with combination therapy using the STAT3 inhibitors napabucasin plus chemotherapy (NCT02231723, NCT02993731). Here, STAT3 is linked to familial pancreatic carcinoma.